

Special Issue

Clinical Development and Challenges in Liver Transplantation for Hepatocellular Carcinoma

Message from the Guest Editors

Liver transplantation remains the cornerstone treatment for early-stage hepatocellular carcinoma (HCC), considering the generally excellent recurrence-free survival rates; however, the scarcity of sufficient organs as well as the eligibility criteria for patients to qualify for liver transplantation have been challenges to overcome. Ideally, criteria for transplantation are based on variables that predict biological behavior in order to select those patients who would benefit the most. Thus, extending the donor pool by living donor programs, alongside the rise in liver perfusion techniques in order to test extended donor grafts, has been implemented. In this Special Issue of *Cancers*, the clinical development and challenges of liver transplantation for HCC will be addressed by highlighting current developments and challenges with respect to transplant criteria, oncological outcomes, bridging/downstaging, neoadjuvant therapy, and donor pool expansion. Dr. Roeland F. de Wilde

Prof. Dr. Jan N.M. IJzermans

Guest Editors

Dr. Roeland F. De Wilde

Dr. Wojciech G. Polak

Prof. Dr. Jan N.M. IJzermans

Deadline for manuscript submissions

closed (16 September 2024)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/180950

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)